Emma Walmsley, GSK CEO (GSK Investor)
GSK drops celiac drug, anti-bacterial vaccine in latest pipeline sweep
On a continued mission to set a high bar for its R&D group — which now gears heavily toward vaccines and specialty medicines — GSK has swept …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
